A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01573533
• Date of registration: 05/04/2012
• Prospective Registration: Yes
• Primary sponsor: Mayo Clinic
• Public title: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
• Scientific title: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte ß3 Integrin
• Date of first enrolment: October 2013
• Target sample size: 9
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01573533
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Canada, United States

Contacts

• Name: Fernando C Fervenza, MD, PhD
• Affiliation: Mayo Clinic

• Name: Michelle Hladunewich, MD, MSc, BSc
• Affiliation: University Health Network, Sunnybrook Health Sciences Centre

Key inclusion & exclusion criteria

Inclusion Criteria:

- FSGS involving native kidneys with a diagnostic biopsy performed within the last 3
years

- Patients >6 years of age and < 80 years of age

- suPAR > 3500 pg ml-1

- Treatment with an ACEI and/or ARB as tolerated for at least 3 months prior to
enrollment to with a target a systolic blood pressure = 140 mmHg and a diastolic
pressure = 90 mmHg in adults and blood pressure readings less than the 95th percentile
for age, gender and height in children in at least 75% of readings

- Proteinuria = 3.0 grams as measured by 24-hour urine collection in adults and urine
protein:creatinine ratio = 1.0 in the first morning urine in children, despite ACE
inhibitor / ARB treatment as tolerated and a minimum of 8 weeks of prednisone therapy
at = 1 mg/kg/day, a trial of calcineurin inhibitor for=> 3 months or a
contraindication/intolerance to such therapy (diabetes, osteoporosis/osteonecrosis,
age >60, BMI =35)

- Negative serum pregnancy test (for women of child bearing age)

- Men and women of reproductive potential must agree to use an acceptable method of
birth control during treatment and for twelve months (1 year) after completion of the
trial

- Able and willing to give written informed consent and comply with study requirements

Exclusion Criteria:

- Estimated GFR < 40 ml/min per1.73m2. The rationale is that patients with advanced
renal failure may progress rapidly towards ESRD.

- Collapsing variant of FSGS, as it is rare and has been associated with an aggressive
course

- Concurrent use of immunosuppressive therapy with the exceptions of prednisone 10
mg/day. Patients who are taking other immunosuppressive therapy, must be off
immunosuppressive medications for equal to or > 3 months prior to enrollment into the
study with the exception of patients demonstrating significant worsening of
proteinuria (of >30% above baseline) during the washout period. These resistant
patients can be treated after 1 month of washout due to the high likelihood of
progression and/or lack of delayed (previous) immunosuppression effect.

- Patients with medical conditions that may cause FSGS (e.g. HIV, lymphoma, heroin use)
or have a secondary form of FSGS due to hyperfiltration injury (massive obesity,
vesicoureteral reflux, or renal mass reduction)

- Type 1 or type 2 diabetes mellitus as diabetic glomerulosclerosis may be contributing
to proteinuria in these patients

- History of serious recurrent or chronic infection

- Presence or suspicion of active infection including TB, HIV, Hepatitis B and HCV with
positive tests for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody
(HBcAb), Hepatitis B virus (HBV), Hepatitis C serology, HIV serology or a positive TB
skin test, which require further investigation to rule out active disease (ie. chest
x-ray)

- Known active infection requiring hospitalization or treatment with intravenous
antibiotics within 4 weeks or oral antibiotics within 2 weeks of the study initiation

- Low immunoglobulins (level to be based on age)

- Absolute neutrophil count < 1.5 x103/mL

- Patients in receipt of a live vaccine within 4 weeks of the study initiation

- Concomitant malignancies or previous malignancies within the last five years, with the
exception of adequately treated basal or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix

- Previous Treatment with a B-cell depleting antibody

- History of severe allergic reactions to humanized or murine monoclonal antibodies

- Treatment with any investigational agent within 4 weeks of the study initiation

- History of major psychiatric disorder, drug or alcohol abuse within the previous 6
months

- Any other disease, metabolic dysfunction, physical examination finding or clinical
laboratory that provides a reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the patient at high risk from treatment
complications



Age minimum: 6 Years
Age maximum: 80 Years
Gender: All

Health Condition(s) or Problem(s) studied

Primary Focal Segmental Glomerulosclerosis

Intervention(s)

Biological: Rituximab

Primary Outcome(s)

Changes in Proteinuria (With Stable Renal Function) [Time Frame: Baseline, 12 months]

Secondary Outcome(s)

Number of Subjects With Complete or Partial Remission Following Treatment [Time Frame: 12 months]

Change in Activation of Podocyte ß3 Integrin [Time Frame: Baseline, 1, 3, 6, 12 months]

Change in suPAR Levels [Time Frame: Baseline, 1, 3, 6 and 12 months]

Secondary ID(s)

12-005640

U54DK083912

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Genentech, Inc.

Rush University Medical Center

National Institutes of Health (NIH)

University Health Network, Toronto

Results

• Results available: Yes
• Date Posted: 10/02/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01573533